Dynavax Technologies Corporation (DVAX) Upgraded to “Hold” at ValuEngine
Dynavax Technologies Corporation (NASDAQ:DVAX) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.
A number of other brokerages have also recently issued reports on DVAX. Royal Bank Of Canada set a $7.00 price objective on Dynavax Technologies Corporation and gave the company a “hold” rating in a research note on Wednesday, July 26th. Zacks Investment Research cut Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. William Blair restated an “outperform” rating on shares of Dynavax Technologies Corporation in a research note on Thursday, July 27th. Cowen and Company restated an “outperform” rating and issued a $30.00 price objective on shares of Dynavax Technologies Corporation in a research note on Thursday, August 10th. Finally, BidaskClub cut Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. Dynavax Technologies Corporation currently has an average rating of “Buy” and an average price target of $24.80.
Shares of Dynavax Technologies Corporation (DVAX) traded up 2.62% during trading on Thursday, hitting $19.55. 1,450,442 shares of the stock traded hands. Dynavax Technologies Corporation has a 1-year low of $3.20 and a 1-year high of $19.80. The stock’s market cap is $1.07 billion. The stock has a 50 day moving average price of $15.55 and a 200-day moving average price of $8.85.
Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.09. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.15 million. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. During the same period in the previous year, the firm earned ($0.75) EPS. Equities analysts forecast that Dynavax Technologies Corporation will post ($1.58) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Dynavax Technologies Corporation (DVAX) Upgraded to “Hold” at ValuEngine” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/07/dynavax-technologies-corporation-dvax-upgraded-to-hold-at-valuengine.html.
A number of institutional investors have recently made changes to their positions in the stock. Lord Abbett & CO. LLC bought a new stake in Dynavax Technologies Corporation in the 2nd quarter valued at about $7,777,000. Family Management Corp raised its stake in Dynavax Technologies Corporation by 72.7% in the 2nd quarter. Family Management Corp now owns 19,000 shares of the biopharmaceutical company’s stock valued at $183,000 after acquiring an additional 8,000 shares during the period. The Manufacturers Life Insurance Company raised its stake in Dynavax Technologies Corporation by 24.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 41,320 shares of the biopharmaceutical company’s stock valued at $399,000 after acquiring an additional 8,092 shares during the period. Cubist Systematic Strategies LLC raised its stake in Dynavax Technologies Corporation by 54.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 3,700 shares during the period. Finally, PointState Capital LP bought a new stake in Dynavax Technologies Corporation in the 2nd quarter valued at about $13,510,000. Institutional investors and hedge funds own 60.23% of the company’s stock.
Dynavax Technologies Corporation Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.